bpc-157 human trials and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded Regeneration or Risk? A Narrative

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)

Use aseptic technique during preparation and reconstitution (if applicable)

Weeks 4-8 Full benefits typically manifest by week 4-6 of consistent use

Once absorbed, it binds to plasma proteins before it is transported around the body

While not FDA-approved for longevity enhancement, its used in supervised medical protocols for healthspan optimization and biological age management